Stock of NovoCure Limited (NVCR) is rising about 34 percent during Thursday morning trading following the U.S. FDA approval of Optune Pax for adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
The company's shares are currently trading at $14.17 on the Nasdaq, up 34.73 percent. The stock opened at $13.34 and has climbed as high as $14.96 so far in today's session. Over the past year, it has traded in a range of $9.82 to $22.95.
The approval was based on the Phase 3 PANOVA-3 trial, which demonstrated a statistically significant improvement in overall survival and delayed pain progression compared to chemotherapy alone.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.